| Name | Title | Contact Details |
|---|---|---|
Emily Wilkins |
Vice President of Compliance & Quality | Profile |
Jonathan Rider |
Chief Information Officer | Profile |
Penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. We design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. Today we have over 1,300 employees with sales operations in North America, Europe, Latin America, Australia and Asia. Members of the Penumbra team agree that this is where their work has meaning -- we are transforming the treatment of some of the world`s most devastating conditions. Penumbra is where everyone`s ideas matter, and where learning and growth are constant.
Lexion Medical LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Korman Healthcare is a Chandler, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Overlook Industries is a Easthampton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.